Page 54 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $6.75
52wk Low $0.40 Cadrenal Therapeutics, Inc. CVKD $0.52
822 A1A North
Ponte Vedra, FL 32082

(USD - in millions) www.cadrenal.com
Market Cap 6.7
Enterprise (2.4)
Basic Shares Out. 13.02 COMPANY OVERVIEW
Float 3.92
Institutional Holdings 0.89% Detailed Analysis:Channelchek.com
Short Interest 0.01
Avg. 90-Day Volume 0.05 Cadrenal Therapeutics Inc is focused on developing a novel therapy
with orphan drug indication, tecarfarin, for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with end-
stage renal disease (on dialysis) and atrial fibrillation (irregular
EPS Data heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a
drug design process that targets a different pathway than most
2021 2022 2023 commonly prescribed drugs for the treatment of thrombosis and AFib.
CQ1 N/A N/A N/A
CQ2 N/A N/A N/A

CQ3 N/A N/A N/A
CQ4 N/A N/A (0.09)
CY N/A N/A (0.64) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.67
ROE (ttm) N/A
Debt-to-Total Cap. (mrq) 0.31
Fiscal Year End 31-Dec
822 A1A NorthPonte Vedra FL 32082

Key Executives
CEO: Pham, Quang
CFO: Szot, Matthew
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures